This is consistent with mounting evidence that CB1R may be part of a core mechanism of fibrogenesis and that CB1R antagonism may have therapeutic potential in several fibrotic disorders, including chronic kidney (31, 32) and liver diseases (33) and cardiomyopathies (34, 35). Here, CNR1 is linked to cardiomyopathy.